(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 20.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.27%.
Immunocore Holdings's revenue in 2026 is $379,590,000.On average, 20 Wall Street analysts forecast IMCR's revenue for 2026 to be $23,062,083,232, with the lowest IMCR revenue forecast at $20,669,467,892, and the highest IMCR revenue forecast at $25,944,843,636. On average, 15 Wall Street analysts forecast IMCR's revenue for 2027 to be $25,869,048,007, with the lowest IMCR revenue forecast at $19,110,099,162, and the highest IMCR revenue forecast at $31,759,884,254.
In 2028, IMCR is forecast to generate $34,852,851,201 in revenue, with the lowest revenue forecast at $25,255,103,416 and the highest revenue forecast at $44,934,175,096.